• <nav id="kqke8"></nav>
  • <input id="kqke8"><u id="kqke8"></u></input>
    <nav id="kqke8"><tt id="kqke8"></tt></nav><nav id="kqke8"></nav>
  • <input id="kqke8"></input>
    <input id="kqke8"><strong id="kqke8"></strong></input>
  • <nav id="kqke8"></nav>


    Industry Overview:
    The bio-pharmaceutical industry in China is undergoing a very rapid growth. According to statistics, the bio- pharmaceutical industry achieved revenue growth-13.95% and profit growth-11.82% in 2014 and the market capacity will be expected to reach $100 billion in 2015. In the next 5-10 years, it will remain growing at the rate of 12%-20%, which attracts many multinational bio-pharmaceutical companies into China and creates lots of investment opportunities.

    The government is also making significant long-term investments in R&D and the field of life sciences is one of the China’s seven strategic pillars of growth. With the a series of laws, regulation and reforms coming out, such as newly revised Drug Registration Regulation (2014), recently issued the Technical Guideline for Development and Evaluation of Biosimilars (interim) (2015), the bio-pharmaceutical industry in China will be more standardized and flourishing in the future.

    But there are still challenges for all market players. Multinational bio-pharmaceutical companies are adapting China regulation and laws, looking for local companies, scientific research institutions and other partners to accelerate new drugs development to serve Chinese patients better; for local pharma companies, they are facing inadequate investment in R&D, shortage of innovation drugs, the technologies and equipment are not as advanced as that in developed countries... Additionally, there is lack of a perfect scientific system about new drug registration, evaluation, approval, market access..., which also restricts the development of biopharmaceutical industry.

    Our Goals:
    Based on this, China Bio-Pharma Executives Summit 2015 will be launched by YIP Events on 19-20 Nov. in Shanghai. We are devoted to offering a communication platform for all market players, specifying related drug regulation laws and reforms, and expect it will be helpful to form a more standardized market and serve Chinese patients better. Meanwhile, we will help participants to recognize the next wave of opportunities and challenges in China, and then adapt their strategies in this transformation era to have a growing business in the future. More than 250 industry executives from government, biopharma company, biotech company, CRO/CMO, scientific research institutions and other market players will attend. During the event, pre-schedule one-to-one meeting is available.

    We are looking forward to your participation!

    Pre-Conference Site Tour

    When: Wednesday, November 18th, 13:00 – 17:00

    Address: Boehringer Ingelheim Biopharmaceuticals (China) Ltd., Zhangjiang High Tech Park, 1010 Longdong Avenue , 201203, Shanghai

    Time: 13:00 pm - 17:00 pm


    12:50 - 13:10 ? Arrival & Sign up
    13:20 - 13:50 ? Opening & Presentation of Boehringer Ingelheim BioChina
    14:00 - 16:30 ? Facility Tour-Manufacture
    ?                       Facility Tour-Transfer Lab/ QC Lab
    ?                       Oasis “Big Bus Tour”
    ?                       Interaction with Boehringer Ingelheim experts
    16:30 - 17:00 ? Wrap up & Farewell

    Day One Morning
    0800 Registration & Morning Coffee
    0855 Chairman Opening Remark
    Qiang Lü
    Chief Scientific Officer and VP, Harbin Gloria Pharmaceuticals

    Biopharmaceutical Revolution Transforms the Industry Ecosystem
    Christopher Round
    President, MSD in China

    0935 Specifying China's Reform of Drug Evaluation and Approval System
    Qun ZHOU
    Chief Engineer, Shanghai Municipal Food and Drug Administration
    1010 Overview of USP Standards for Biologics
    Bingbing FENG
    Vice President & General Manager, U.S. Pharmacopeia–China
    1040 Refreshment Break & Networking
    1100 Update on European GMP Requirements
    Lance Smallshaw
    Executive Committee of the European Compliance Academy (ECA)
    Associate Director of the CaSSS

    BioPharma Capabilities
    Gianluca Pettiti
    President, Thermo Fisher Scientific China


    Panel Discussion: Adapting China Regulation Environment --Challenges and
    Opportunities under China FDA Reform
    Will CHEN, Executive Director of Regulatory Affairs, WuXi AppTec
    Kezhou ZHANG, Vice President of Clinical Development, Medical and Regulatory Affairs, Novo
    Ning XU, Executive Vice President, Head of Clinical Development and Regulatory Affairs,
    James GUO, VP for Strategic Planning and Drug Regulatory affairs, Shanghai Henlius Biotech

    1230 Lunch & Networking (E-CAFé, Floor B)
    Day One Afternoon
    1400 Panel Discussion: Opportunities and Challenges in China and Integrating China into Global
    Fitz De Smet, Vice President, Marketing & Business Development, Thermo Fisher Scientific
    Satoru Noguchi, Area Head of Greater China and Chairman of Takeda (China)
    Chris Round, President, MSD in China
    Jean-Christophe Pointeau, General Manager, Commercial Operations, Sanofi China
    1450 ‘Open Innovation’ Strategy--Fostering Innovation Ecosystem through
    Collaborating with External Partners to Accelerate Drug Development Process
    Edward HU
    Chief Financial Officer & Chief Investment Officer, WuXi AppTec.
    1530 Refreshment Break & Networking
    1600 How Outsourcing Can Add Value to Your Process Chain
    Barbara Esch
    Head of Marketing, Communication & Business Intelligence for the global Contract Manufacturing
    Business (CMB) in Biopharmaceuticals
    Boehringer Ingelheim Biopharmaceuticals GmbH
    1640 Tackle Challenges of Characterization of Biosimilar Drugs with Cutting-edge Mass
    Rohan A Thakur
    Senior Vice President, Bruker Daltonics
    1720 Panel Discussion: Exploring R&D Innovation Potential in China
    Jim LI, Chief Executive Officer, Sundia MediTech Company
    Jennifer HU, Vice President, Head of Global Drug Discovery-Innovation Center China, Bayer
    Amber CAI, Head NIBR Shanghai Operations, Novartis Institutes for BioMedical Research
    Kezhou ZHANG, Vice President of Clinical Development, Medical and Regulatory Affairs, Novo
    1800 Closing Words
    1820 Welcome Dinner (ALWAYS CANTONESE, Floor B)
    Day Two Morning
    0855 Chairman Opening Remarks
    Mingde XIA
    Senior Director, Johnson & Johnson Innovation Center

    Promoting China's Reform of Drug Evaluation and Approval System; Improving the Quality
    and Efficiency of Drug Evaluation and Approval System
    Hui ZHANG
    Director of Biological Products Division--Department of Drug and Cosmetics Registration, China
    Food and Drug Administration (CFDA)

    0930 Development of Open–Access Integrated Technology Platforms to Expedite
    Biologics Development
    Weichang ZHOU
    Senior Vice President, Biologics Development and Manufacturing, WuXi AppTec

    1000 Panel Discussion: What Are the Core Capabilities to Develop, Manufacture and
    Commercialize Biosimilars in Emerging Market?
    Emily TAN, Vice President, Portfolio Management APAC, PAREXEL
    Weichang ZHOU, Senior Vice President, Biologics Development and Manufacturing,
    WuXi AppTec
    Scott LIU, CEO, Shanghai Henlius Biotech
    Ting XU, Founder and CEO, AlphaMab
    Zheru ZHANG, CEO, Shanghai JMT-Bio
    1030 Refreshment Break & Networking
    1055 Treating Tumor with Active Cellular Immunotherapy--a SOTIO Perspective
    Yong ZHANG
    Chief Medical Officer, SOTIO Medical Research (Beijing) Co., Ltd
    1125 Platform Technologies for Fingerprinting Biosimilars
    Kenneth J. Fountain
    Director, Biopharmaceutical Business Development, Waters Corporation
    1155 Cell Culture Media Supplements:Effects on Performance and Protein Quality
    Matthias Brand
    Senior Market Development Manager, BD Biosciences –Advanced Bioprocessing, Greater

    1230 Networking Lunch (E-CAFé, Floor B)
    Day Two Afternoon
    1400 Panel Discussion: Collaboration Strategies and Partnership Models in China
    Mingde XIA, Senior Director, Johnson & Johnson Innovation Center
    Weikang TAO, Vice President of Jiangsu Hengrui Medicine Co., Ltd., CEO of the R&D Center,
    Hengrui Medicine
    Joe ZHOU, CEO of Genor BioPharma Co. Ltd., VP and R/D Director of Walvax Group
    Guochun LI, Head of Biologics, Harbin Gloria Pharmaceuticals
    Siqi TAN, Vice president of Lab Solutions China, Thermo Fisher Scientific
    1440 Boehringer Ingelheim BioChina BioLab & OASIS – BI’s Newest Members in its
    Global BioManufacturing Network
    Axel Schleyer
    VP Business Development & Key Account Management, Regions Americas and Asia/Pacific
    Boehringer Ingelheim Biopharmaceuticals
    1520 Clinical Development of Biologics
    Emily TAN
    Vice President, Portfolio Management APAC, PAREXEL
    1550 Refreshment Break & Networking
    1620 Panel Discussion: China Clinical Trials will Enter into a New Era
    Moderator: Johnathan Lee, Head of Greater China Project Leadership, Quintiles
    Ning XU, Executive Vice President, Head of Clinical Development and Regulatory Affairs,
    Ye HUA, Senior Vice President, Head of Clinical Development & Regulatory Affairs, Hutchison
    Joan Shen, VP, Development Head, China R&D and Scientific Affairs, Johnson & Johnson

    Panel Discussion: Data-Driven Models of R&D--How to Improve R&D Productivity through
    Making Better Use of Existing Data?
    Moderator: Jerry Wang, Head of Biostatistics & Statistical Programming, Merck Serono China
    Ye HUA, Senior Vice President, Head of Clinical Development & Regulatory Affairs, Hutchison
    Paul Whitehead, Informatics Center Head, Roche
    Ouhong Wang, Head of Biostatistics and Statistical Programming, Amgen


    Closing Words


      Media Partner

    天堂AV 国产 亚洲 日韩 制服